Home » Stocks » XAIR

Beyond Air, Inc. (XAIR)

Stock Price: $6.22 USD -0.28 (-4.31%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $6.16 -0.06 (-0.97%) Jan 15, 7:21 PM
Market Cap 107.88M
Revenue (ttm) 695,801
Net Income (ttm) -22.06M
Shares Out 17.12M
EPS (ttm) -1.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $6.22
Previous Close $6.50
Change ($) -0.28
Change (%) -4.31%
Day's Open 6.44
Day's Range 6.13 - 6.50
Day's Volume 257,125
52-Week Range 3.94 - 10.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 2 days ago

Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time Call scheduled for Tuesday, February 9th at 4:30 pm Eastern Time

Seeking Alpha - 4 weeks ago

Beyond Air Offers Compelling Value Heading Into Its First Potential Product Approval

GlobeNewsWire - 1 month ago

GARDEN CITY, N.Y., Nov. 19, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (...

Seeking Alpha - 2 months ago

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q2 2021 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

Potential to revolutionize nitric oxide therapy by eliminating need for cumbersome cylinders creating im proved economics and safety in hospital setting

GlobeNewsWire - 2 months ago

Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time Call scheduled for Wednesday, November 11th at 4:30 pm Eastern Time

GlobeNewsWire - 2 months ago

Patients with pneumonia caused by any virus, including SARS-CoV-2, will be considered for enrollment

GlobeNewsWire - 2 months ago

New in vivo data for colon cancer show anti-tumor immunity in 100% of mice

GlobeNewsWire - 2 months ago

In vitro data support development of nitric oxide as a potential coronavirus therapy that acts within hours

GlobeNewsWire - 2 months ago

150 ppm nitric oxide was statistically significant compared to both control and 85 ppm nitric oxide arms on the primary and key secondary endpoints

GlobeNewsWire - 3 months ago

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (...

GlobeNewsWire - 4 months ago

GARDEN CITY, N.Y., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxid...

GlobeNewsWire - 4 months ago

GARDEN CITY, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxid...

GlobeNewsWire - 4 months ago

GARDEN CITY, N.Y., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide...

GlobeNewsWire - 5 months ago

Heterogeneity in M. abscessus susceptibility to NO

Seeking Alpha - 5 months ago

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha - 5 months ago

Beyond Air Has Huge Long-Term Potential

Zacks Investment Research - 5 months ago

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 5 months ago

Conference call at 8:30 a.m. ET Conference call at 8:30 a.m. ET

Benzinga - 6 months ago

Shares of Beyond Air Inc (NASDAQ:XAIR) rose by 2.9% from the previous closing price.

Seeking Alpha - 6 months ago

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q4 2020 Results - Earnings Call Transcript

GlobeNewsWire - 6 months ago

Reported positive clinical data for third bronchiolitis study using high concentration nitric oxide, achieving primary and key secondary endpoints

GlobeNewsWire - 6 months ago

Data demonstrate the ablation of solid tumors with nitric oxide

Zacks Investment Research - 7 months ago

AIT Therapeutics, Inc. (XAIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 7 months ago

GARDEN CITY, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide...

GlobeNewsWire - 7 months ago

Anticipate study start in June 2020 Anticipate study start in June 2020

GlobeNewsWire - 7 months ago

High concentration nitric oxide (150 ppm) is statistically significant compared to both low concentration nitric oxide (85 ppm) and control arms on both the primary endpoint and the key seco...

GlobeNewsWire - 8 months ago

GARDEN CITY, N.Y., May 15, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide ...

GlobeNewsWire - 8 months ago

Term to run through May 2023

GlobeNewsWire - 9 months ago

Food and Drug Administration (FDA) agrees to a trial using  the LungFit ™ system to treat COVID-19 patients

GlobeNewsWire - 9 months ago

Prepared to test LungFit™ BRO in COVID-19 patients in a clinical study starting in April pending FDA approval of recently submitted IDE (investigational device exemption) Prepared to test Lung...

Market Watch - 10 months ago

Beyond Air Inc. XAIR, +17.05% said Monday that it submitted an investigational device exemption to the Food and Drug Administration (FDA) as it seeks authority to market its nitric oxide devic...

Seeking Alpha - 10 months ago

Beyond Air: Buy The Stock Ahead Of March 5 Analyst Day

Seeking Alpha - 11 months ago

Beyond Air, Inc. (XAIR) CEO Steve Lisi on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

AIT Therapeutics, Inc. (XAIR) delivered earnings and revenue surprises of -30.30% and -45.39%, respectively, for the quarter ended December 2019.

GlobeNewsWire - 1 year ago

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...

GlobeNewsWire - 1 year ago

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...

GlobeNewsWire - 1 year ago

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...

GlobeNewsWire - 1 year ago

GARDEN CITY, N.Y. and REHOVOT, Israel, Dec. 09, 2019 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing ...

GlobeNewsWire - 1 year ago

Exclusive five-year global agreement

About XAIR

Beyond Air, a clinical-stage medical device and biopharmaceutical company, develops inhaled nitric oxide (NO) to treat respiratory infections, and gaseous NO to treat solid tumors. The company is developing LungFit system, a NO generator and delivery system, which is in clinical trials for the treatment of lung infections, persistent pulmonary hypertension of the newborn, severe acute respiratory syndrome coronavirus 2, bronchiolitis, and nontuberculous mycobacteria.The company was formerly known as AIT Therapeutics, Inc. and changed its name t... [Read more...]

Industry
Medical Devices
CEO
Steven Lisi
Employees
23
Stock Exchange
NASDAQ
Ticker Symbol
XAIR
Full Company Profile

Financial Performance

In 2019, Beyond Air's revenue was $1.39 million, a decrease of -82.00% compared to the previous year's $7.72 million. Losses were -$19.94 million, 204.1% more than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Beyond Air stock is "Buy." The 12-month stock price forecast is 13.25, which is an increase of 113.02% from the latest price.

Price Target
$13.25
(113.02% upside)
Analyst Consensus: Buy